Browse > Article
http://dx.doi.org/10.4014/jmb.1410.10044

Effects of 1,7-Substituted Methylxanthine Derivatives on LPS-Stimulated Expression of Cytokines and Chemokines in Raw 264.7 and HK-2 Cells  

Kang, Joo-Yeon (College of Pharmacy, Duksung Women's University)
Shin, Hea-Soon (College of Pharmacy, Duksung Women's University)
Publication Information
Journal of Microbiology and Biotechnology / v.25, no.2, 2015 , pp. 296-301 More about this Journal
Abstract
Chronic kidney diseases are based on uncontrolled immunological and inflammatory responses to pathophysiological renal circumstances such as glomerulonephritis, which is caused by immunological mechanisms of glomerular inflammation with increased production of renal pro-inflammatory cytokines. Pentoxifylline (PTX) exhibits anti-inflammatory properties by inhibiting cytokine and chemokine production through aggregation of erythrocytes and thrombocytes. We synthesized a series of 1,7-substituted methylxanthine derivatives by the Traube purine reaction, and the formation of purine ring was completed through nitrosation, a reduction of the nitroso to the amine by catalytic hydrogenation as derivatives of PTX. Then we studied biological activities such as renal anti-inflammatory effects of the synthesized compounds in the production of cytokines such as nitric oxide (NO), interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) and of chemokines such as monocyte chemoattractant protein-1 and IL-8 in Raw 264.7 and HK-2 cells. Renal antiinflammatory activities of this novel series of N-1 and N-7-substituted methylxanthine showed that the N-7 methyl-group-substituted analogs (S7b) showed selective 61% and 77% inhibition of the production of NO and IL-8. The other replacement of the N-1-(CH2)4COCH3 roup, as in the case of compound S6c, also showed an effective 50% and 77% inhibition of TNF-α and IL-8 production in LPS-stimulated Raw 264.7 and HK-2 cells.
Keywords
Anti-inflammatory effect; pentoxifylline; pro-inflammatory cytokine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Giocoechea M, García de Vinuesa S, Quiroga B, Verdalles U,Barraca D, Yuste C, et al. 2012. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J. Nephrol. 25: 969-975.   DOI   ScienceOn
2 Hernández E, Correa A, Bucio L, Souza V, Kershenobich D, Gutiérrez-Ruiz MC. 2002. Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol. Res. 46: 435-443.   DOI   ScienceOn
3 Kasap B, Türkmen M, Kiray M, Kuralay F, Soylu A, Tuğyan K, Kavukçu S. 2013. Effects of pentoxifylline on gentamicininduced nephrotoxicity. Ren. Fail. 35: 1376-1381.   DOI   ScienceOn
4 Kim JD, Kang YK. 2013. 2012 National Health Insurance Statistical Yearbook, pp. 557 National Health Insurance Service, Health Insurance Review & Assessment Service, Seoul.
5 Lee SY, Kim SI, Choi ME. 2014. Therapeutic targets for treating fibrotic kidney diseases. Transl. Res. DOI: 10.1016/ j.trsl.2014.07.010.   DOI
6 Magnusson M, Gunnarsson M, Berntorp E, Björkman S, Höglund P. 2008. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy human. Eur. J. Pharmacol. 581: 290-295.   DOI   ScienceOn
7 Modzelewski B, Janiak A. 2004. Pentoxyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis. Med. Sci. Monit. 10: BR233-BR237.
8 Ortega LM, Fornoni A. 2010. Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int. J. Interferon Cytokine Mediator Res. 2: 49-62.   DOI
9 Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. 2005. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol. Scand. 49: 41-46.   DOI   ScienceOn
10 Berk B, Akgün H, Erol K, Sirmagül B, Gao ZG, Jacobson KA. 2005. New 8-substituted xanthine derivatives as potent bronchodilators. Farmaco 60: 974-980.   DOI   ScienceOn
11 Bohm L, Theron T, Binder A. 2000. Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Bioch. Biophys. Acta 1499: 1-10.   DOI   ScienceOn
12 Bhat VB, Madyastha KM. 2001. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem. Biophys. Res. Commun. 288: 1212-1217.   DOI   ScienceOn
13 Çakmak SK, Çakmak A, Gönül M, Kiliç A, Gül Ü. 2012. Pentoxifylline use in dermatology. Inflamm. Allergy Drug Targets 11: 422-432.   DOI
14 Chung AC, Lan HY. 2011. Chemokines in renal injury. J. Am. Soc. Nephrol. 22: 802-809.   DOI   ScienceOn
15 Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, et al. 2005. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int. 67: 1753-1761.   DOI   ScienceOn
16 Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. 2006. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuria primary glomerular disease. Kidney Int. 69: 1410-1415.   DOI
17 Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. 2005. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 67: 1812-1820.   DOI   ScienceOn
18 Zhou Q, Zheng F, Hou F. 2009. Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. Acta Phamacol. Sin. 30: 98-106.   DOI   ScienceOn
19 Ozer MK, Asci H, Oncu M, Yesilot S, Savran M, Bayram D, Cicek E. 2009. Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats. Ren. Fail. 31: 134-139.   DOI   ScienceOn
20 Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R. 2006. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am. J. Physiol. Renal Physiol. 291: F1090-F1095.   DOI